[go: up one dir, main page]

PE20081395A1 - Derivados de aril sulfamida y metodos para su uso - Google Patents

Derivados de aril sulfamida y metodos para su uso

Info

Publication number
PE20081395A1
PE20081395A1 PE2007001769A PE2007001769A PE20081395A1 PE 20081395 A1 PE20081395 A1 PE 20081395A1 PE 2007001769 A PE2007001769 A PE 2007001769A PE 2007001769 A PE2007001769 A PE 2007001769A PE 20081395 A1 PE20081395 A1 PE 20081395A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
aryl
substituted
compounds
Prior art date
Application number
PE2007001769A
Other languages
English (en)
Inventor
Casey Cameron Mccomas
Stephen Todd Cohn
Mathew L Crawley
Andrew Fensome
Joel Adam Goldberg
Douglas John Jenkins
Callain Younghee Kim
Page Erin Mahaney
Charles William Mann
Michael Anthony Marella
Neill David John O
Joseph P Sabatucci
Eugene Anthony Terefenko
Eugene John Trybulski
An Thien Vu
Richard Page Woodworth
Puwen Zhang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20081395A1 publication Critical patent/PE20081395A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ARIL SULFAMIDA DE FORMULA (I) DONDE n ES DE 0 A 4; m ES DE 0 A 6; X ES O, S, S(=O), S(=O)2, ENTRE OTROS; R1 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), HALO, CF3, ENTRE OTROS; R2 ES ARILO(C6-C10) O HETEROARILO SUSTITUIDOS CON 0-3 R9, EN DONDE R9 ES HALO, CF3, OCF3, NITRO, ENTRE OTROS; R3 ES H, ARILO(C6-C10), ALQUILO(C1-C4), ENTRE OTROS; Y ES C; O X E Y JUNTOS FORMAN -C=C-, ARILENILO SUSTITUIDO CON 0-3 R10, EN DONDE R10 ES ALQUILO(C1-C6), ALCOXI(C1-C6), HALO, CF3, NITRILO, ENTRE OTROS; R4 ES H, ALQUILO(C1-C4), ARILALQUILO(C7-C16) SUSTITUIDO; R6 ES ALQUILO(C1-C4), HIDROXI, HALO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-[3-(4-CLOROFENIL)-2,2-DIOXIDO-2,1,3-BENZOTIADIAZOL-1(3H)-IL]-N-METILPROPAN-1-AMINA, N-{3-[3-(4-CLOROFENIL)-2,2-DIOXIDO-2,1,3-BENZOTIADIAZOL-1(3H)-IL]PROPIL}CICLOPROPANAMINA, N-{3-[3-(2,6-DIFLUOROFENIL)-2,2-DIOXIDO-2,1,3-BENZOTIADIAZOL-1(3H)-IL]PROPIL}CICLOHEXANAMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE RETOMA DE MONOAMINA SIENDO UTILES EN EL TRATAMIENTO DE DISFUNSION SEXUAL, INCONTINENCIA URINARIA, FIBROMIALGIA, TRASTORNO DE ANSIEDAD
PE2007001769A 2006-12-12 2007-12-12 Derivados de aril sulfamida y metodos para su uso PE20081395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86964406P 2006-12-12 2006-12-12

Publications (1)

Publication Number Publication Date
PE20081395A1 true PE20081395A1 (es) 2008-09-17

Family

ID=39273293

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001769A PE20081395A1 (es) 2006-12-12 2007-12-12 Derivados de aril sulfamida y metodos para su uso

Country Status (20)

Country Link
US (4) US20080161366A1 (es)
EP (1) EP2061776A1 (es)
JP (1) JP2010512401A (es)
KR (1) KR20090087506A (es)
CN (1) CN101600701A (es)
AR (1) AR064318A1 (es)
AU (1) AU2007333593A1 (es)
BR (1) BRPI0720289A2 (es)
CA (1) CA2671844A1 (es)
CL (1) CL2007003590A1 (es)
CR (1) CR10866A (es)
EC (1) ECSP099411A (es)
MX (1) MX2009006359A (es)
NO (1) NO20092092L (es)
PE (1) PE20081395A1 (es)
RU (1) RU2009121017A (es)
SV (1) SV2009003295A (es)
TW (1) TW200843753A (es)
WO (1) WO2008073459A1 (es)
ZA (1) ZA200904109B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076502A1 (en) * 2007-12-12 2009-06-18 Wyeth Methods for the preparation of hydroxy-substituted aryl sulfamide compounds
GB0813694D0 (en) * 2008-07-25 2008-09-03 Glaxo Group Ltd Compounds
JP2013521290A (ja) * 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
CN104024217B (zh) 2011-11-07 2017-09-15 埃莫里大学 用于治疗或预防与内分泌功能障碍相关的症状的三环含氨基化合物
US9867813B2 (en) * 2015-11-17 2018-01-16 Thomas Daly Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
CN107337616A (zh) * 2017-07-13 2017-11-10 上海昕盛医药科技有限公司 一种盐酸班布特罗杂质f的合成方法
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
CN112351969A (zh) * 2018-06-21 2021-02-09 塞莱斯蒂亚生物技术股份公司 用于制备氨基二芳基醚和氨基二芳基醚盐酸盐的方法
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド
CN116003261A (zh) * 2022-12-19 2023-04-25 江苏康恒化工有限公司 新型聚氨酯扩链剂2-氨基-2’-氯二苯胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3177221A (en) * 1963-02-05 1965-04-06 Mcneilab Inc 2, 1, 3-benzothiadiazoline-2, 2-dioxides
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
ZA966885B (en) * 1995-08-22 1998-02-16 Du Pont Merck Pharma Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors.
GB9825413D0 (en) * 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
AU2001286454B2 (en) * 2000-08-14 2006-09-14 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
JP4380992B2 (ja) * 2001-04-18 2009-12-09 ユーロ−セルティーク エス．エイ． ノシセプチン類似体
CN1589153A (zh) * 2001-12-28 2005-03-02 武田药品工业株式会社 排尿紊乱的预防或治疗
US20080188478A1 (en) * 2005-04-26 2008-08-07 Pfizer Inc. Compounds Useful In Therapy
EP1934193A1 (en) * 2005-09-29 2008-06-25 Wyeth a Corporation of the State of Delaware Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake

Also Published As

Publication number Publication date
CL2007003590A1 (es) 2008-02-29
MX2009006359A (es) 2009-06-26
US7601722B2 (en) 2009-10-13
ZA200904109B (en) 2010-04-28
CN101600701A (zh) 2009-12-09
WO2008073459A1 (en) 2008-06-19
EP2061776A1 (en) 2009-05-27
NO20092092L (no) 2009-08-19
ECSP099411A (es) 2009-07-31
US20080167303A1 (en) 2008-07-10
AU2007333593A1 (en) 2008-06-19
KR20090087506A (ko) 2009-08-17
TW200843753A (en) 2008-11-16
CA2671844A1 (en) 2008-06-19
US20100029641A1 (en) 2010-02-04
SV2009003295A (es) 2009-10-29
BRPI0720289A2 (pt) 2014-02-04
US20080161366A1 (en) 2008-07-03
RU2009121017A (ru) 2011-01-20
AR064318A1 (es) 2009-03-25
JP2010512401A (ja) 2010-04-22
US20080194654A1 (en) 2008-08-14
CR10866A (es) 2009-07-14

Similar Documents

Publication Publication Date Title
PE20081395A1 (es) Derivados de aril sulfamida y metodos para su uso
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
GB0505048D0 (en) Compounds with PGD antagonist activity
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
RU2502730C2 (ru) Сульфонамидные соединения и их применение
PE20081265A1 (es) Compuestos de biaril eter urea como inhibidores de faah
PE20081359A1 (es) Compuestos de azabenzotiofenil como inhibidores de la quinasa mek
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
EA200870362A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
WO2005100350A8 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
PE20050631A1 (es) Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina
JP2008540554A5 (es)
PE20071022A1 (es) Compuestos derivados de dibencilamina como inhibidores de la proteina de transferencia del colesteril ester (cept)
AR070701A1 (es) Derivados de fluoroglicosidos aromaticos, medicamentos que comprenden estos compuestos y uso de los mismos para producir un medicamento
GB0517191D0 (en) Compounds
RU2012120759A (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
PE20091887A1 (es) Fenoxibenzamidas sustituidas
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
HRP20090474T1 (hr) Postupak i intermedijeri za sintezu kaspofungina
GB0517175D0 (en) Compounds
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.

Legal Events

Date Code Title Description
FD Application declared void or lapsed